Median incomes have not kept pace with the inflation rate for job-based health insurance costs, straining family budgets. » Read More
The U.S. Food and Drug Administration issued emergency authorization for a Zika diagnostics test from Swiss drugmaker Roche.
Singapore has confirmed 56 cases of locally transmitted Zika virus infection, while ramping up health screenings and mosquito control efforts.
Alere fell 3 percent after it sued Abbott to compel it to get all antitrust approvals required to complete its $5.8 billion merger.
Mylan is trying to win over critics by issuing coupons to help consumers pay for its high-priced EpiPen. Don't be fooled, says Vox writer Sarah Kliff.
Wall Street likes health care despite its vulnerability to political headwinds and underperformance this year.
Obamacare rates are 7 percent less in states with greater Medicaid eligibility, a new analysis says.
Mylan has raised the price of EpiPens more than 400 percent in recent years. The medicine inside costs $1.
CNBC's Jim Cramer fired back Thursday on comments from Mylan CEO Heather Bresch about pricing of the auto-injection device EpiPen.
Under pressure, Mylan plans to boost access to its EpiPen Auto-Injector by expanding existing programs for patients who are facing higher costs.
Pharmaceutical company Mylan has reduced the cost of EpiPens for some people — but at the end of the day, its CEO told CNBC she has a business to run.
Should you buy long-term-care insurance? That's the question for workers nearing retirement. The cost of coverage and care is rising.
Price increases on life-saving EpiPens have parents outraged — but the CEO of the company that makes them said no one's more frustrated than her.
Most HealthCare.gov customers could buy health plans for under $100 per month next year even if prices grew by 25 percent.
Mylan announced plans to boost access to its EpiPen Auto-Injector by expanding programs for patients who are facing higher out-of-pocket costs.
Heather Bresch is the daughter of a U.S. senator, incorporated her American company in the Netherlands and got an MBA she wasn't entitled to.
Nancy Retzlaff, has filed a federal complaint against Turing Pharmaceuticals, the New York Times reports.
Get the best of CNBC in your inbox